tion of medical and nursing care, and nutritional intervention, which have improved the survival rate in this most challenging group of patients from 60% to 88%. This has been achieved with good quality of life despite a high perioperative morbidity and the greater technical difficulties related to the small size of the patient.
Abstract
Objective-To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre.
Design-Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a miiimum of 12 months (median 48 months) after an intended dose of 3-7 MBq/g thyroid tissue corrected to a 100% uptake ofiodine-131 in 24 hours.
Patients-69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences. The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on.
Main outcome measurements-Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year.
Results-56 patients were treated with a single dose of 1311, 12 with two doses, and one with four doses. In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 ml at 24 months in the 39 patients in whom this was measured during follow up. The median reduction was 40 ml (60% reduction, p<O0OOOl), half of which occurred within three months. Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume. Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4-8% to 3844%). Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis. Only one patient was dissatisfied with the result; she was referred for operation six months after treatment.
Introduction
The yearly growth rate of non-toxic multinodular goitres has been estimated at 10 Pretreatment, a 99-Tc thyroid scan, was performed in all patients with a gamma camera, using 3 mCi 99mTc-pertechnetate. Serum concentrations of thyroxine (normal range 59-129 nmol/l) and triiodothyronine (normal range 1 0-2-5 nmol/l) and a triiodothyronine resin uptake test (normal range 0-80-1 25 arbitrary units) were determined by in house methods (assay variation was 6%, 10%, and 5% respectively. Free thyroxine index and free triiodothyronine index were calculated as the total hormone concentration times the resin uptake and given in arbitrary units. Serum concentration of thyroid stimulating hormone was determined, up to 1986, by a previously described radioimmunoassay.'0 From 1986 to 1989 we used an immunoradiometric assay (Boots-Celltech, England) with an intra-assay coefficient of variation of 2-3-4-7% and a detection limit of 0 03 mU/l. From 1989 we used the Delfia hTSH assay (Wallac, Turku, Finland), which has an intra-assay coefficient of variation of 3 7-5 4% and a detection limit of 0 03 mU/l.
Hyperthyroidism was defined as a subnormal serum concentration of thyroid stimulating hormone with a concomitant increase in serum concentration of thyroxine or triiodothyronine, or both. Hypothyroidism was defined as a raised serum thyroid stimulating hormone concentration concomitant with a decrease in free thyroxine index. Patients with raised serum thyroid stimulating hormone concentrations but normal free thyroxine index were classified as having compensated hypothyroidism (seven of 11 hypothyroid patients). These patients were treated with levothyroxine for subjective complaints compatible with hypothyroidism (mainly weight gain) and increasing serum thyroid stimulating hormone concentrations. In the statistical analysis and in the results section these patients were classed as hypothyroid.
Ultrasonic scanning and calculation of total thyroid volume (normal range 9-6-27-6 ml) were performed as previously described10 with a compound scanner (type 1846, Bruel and Kjaer, Naerum, Denmark Ten subjects (all women) with a median age of 60 (range 46-83) years and an initial thyroid volume of 45 (25-161) ml need special mention. All were treated with one dose of '3I. Follow up data on thyroid volume were not available for these women, but several developed hypothyroidism. So that the prevalence of hypothyroidism would not be underestimated these patients were included. Six of the 10 patients were euthyroid when lost to follow up. Of these six, two patients died of unrelated reasons at age 80 and 85, three years and one year, respectively, after "'I treatment. One patient emigrated, and two were referred back to their private practitioners after 12 and 24 months. One patient was dissatisfied with the effect of treatment and was referred for operation six months after treatment; at this time the initial thyroid volume of 30 ml was unchanged and she was euthyroid. The remaining four of the 10 patients were treated with levothyroxine-three because of compensated hypothyroidism-within 12 months of treatment and referred back to their private practitioner.
STATISTICAL EVALUATION
When calculating the incidence of hypothyroidism we used life table analysis. Longitudinal changes in thyroid gland volume were analysed by the Page test for trend.'2 Because of the lack of volume estimations from different patients at different times, one value obtained before and two values obtained after '3'I treatment were used for this test. The values after treatment were the average of the results from six and 12 months, and 24 and 36 months. When both values were missing the patient was excluded from the Page test evaluation, and when only one value was available this value was used. Significance level was chosen at p<0-05.
Results
Median initial thyroid volume in the 69 patients was 74 (range 21-296). All patients were clinically and biochemically euthyroid, but in 21 patients serum thyroid stimulating hormone concentrations were subnormal ( < 0 4 mU/l).
Fifty six patients (51 women) were treated with a single '3'I dose and were followed for a median of 60 Nine patients developed hypothyroidism after a median of six (range 3-36) months. Median ''I dose was 474 MBq (296-1110) and thyroid volume was reduced from a median of48 (28-93) ml to 15 (8-71) ml (69% decrease, p < 0 05) in the five patients in whom it was measured (fig 2) . Five of these patients had compensated hypothyroidism with normal free thyroxine index and raised serum thyroid stimulating hormone concentrations (7, 12, 16, 27 , and 29 mU/l).
Two patients developed hyperthyroidism three months after 131I treatment. Both were treated with antithyroid drugs for several months and thereafter remained euthyroid. Figure 3 shows thyroid volumes. Neither patient had a family history of Graves' disease or other thyroid disorders, but antibodies to thyroid stimulating hormone receptor and thyroid peroxidase were not measured, so evidence for or against Graves' disease cannot be provided.
Twelve patients were treated with a second dose of '31I, mainly to reduce thyroid volume furither. They were followed for a median of 48 (12-72) months from the first treatment, with a median of 12 months between the two treatments. Median initial 131I dose was 611 (252-925) MBq, and the median second dose was 740 (222-925) MBq. Seven of these patients received a lower initial dose than intended. Nine patients remained euthyroid during the follow up period. In these patients the initial 131' dose reduced thyroid volume from 90 (34-296) ml to 84 (25-223) ml (p < 0 05) and the second dose reduced thyroid volume from 84 (25-223) ml to 69 (11-130) ml (p<0 0005; fig 4) . Within the observation period thyroid size was normalised in one patient.
One patient developed permanent hypothyroidism 16 months after and another 24 months after the second 'II dose. Figure 2 gives thyroid volume data. Both patients had compensated hypothyroidism with serum thyroid stimulating hormone concentrations of 7 and 11 mU/l.
One patient developed hyperthyroidism one month after the initial 131I dose and was treated with antithyroid drugs for 10 months. Thereafter another "'I dose was given and the patient has been euthyroid since. Figure 3 gives thyroid volume data.
One patient received four doses of "'I (800, 555, 555, and 740 MBq); thyroid volume decreased from 96 ml to 56 ml and the patient has remained euthyroid (fig 4) .
During We encountered no cases of exacerbation of obstructive symptoms, and only one of the patients has been referred for thyroidectomy.
Discussion
Sporadic and-in countries with relatively low daily iodine intake-ndemic goitre is a fairly common condition. In Denmark, where there is a low to borderline iodine intake of 50-80 ,ug/day,'3'4 a minimum of 5% of the adult population is estimated to have a multinodular non-toxic goitre.'0 Thyroid suppression with thyroxine or triiodothyronine, effective at least transiently in diffuse non-toxic goitre,2 is probably without lasting benefit in multinodular goitre.35 Spontaneous reduction in goitre size is unlikely; on the contrary, an average yearly growth rate of up to 20% is to be expected.' Surgery is effective and rapidly relieves pressure related symptoms, but goitre recurs in at least 10-15% of patients,'6 the number depending on definition and length of follow up but probably independent of whether thyroxine is given after operation.' Reoperation for whatever indication increases the probability of complications, particularly hypoparathyroidism and laryngeal nerve damage." 5'6 The larger the glands the more likely the operative complications. Furthermore, many patients with large multinodular goitres are elderly, and surgery may be contraindicated by other medical conditions. Additionally, a number of patients refuse to be operated on. In this light we sought to evaluate the long term outcome of 131I treatment for non-toxic multinodular goitre.
EFFECT ON THYROID VOLUME This longitudinal prospective long term study comprising 69 patients showed an overall decrease of 34% in ultrasonically determined thyroid volume after 13'I treatment after 12 months and 55% after 24 months. As the expected spontaneous growth rate is 10-20% a year,' the reduction could well be even more pronounced. Most patients were treated with one dose of '3I, and half of the achievable thyroid volume reduction of 60% (at 24 months) occurred within three months of treatment. Patients offered repeat treatment showed a reduction in volume after the first 13'I dose; a second dose was generally given when the initial volume reduction was inadequate, mostly in patients in whom the first dose was lower than intended due to large glands or a low uptake of "'3I. Patients with thyroiditis and hyperthyroidism did not have an increase in thyroid volume. Generally the reduction was of the same order in these patients as that seen after 'III treatment in toxic multinodular goitre.7 Other researchers who have shown reductions in goitre size after "'3I treatment in patients with multinodular goitre have used less accurate methods (palpation, neck circumference, and scintigraphy) and scantier observations. '7-20 Although 10 of the 59 patients had a small increase in thyroid volume within the first month this in no case caused an exacerbation of obstructive or other symptoms. Surprisingly, 20 patients had normal or only slightly increased thyroid volume (< 50 ml) before treatment, but this is in part explained by recurrence of a unilateral symptomatic goitre in patients with a previous hemithyroidectomy. The average reduction in thyroid volume was independent of initial size of the thyroid. This is not surprising since the dose of "'I was adjusted for thyroid size.
SIDE EFFECTS
The cumulative risk of hypothyroidism five years after '31I treatment was 22%, very different from the risk of 100% after eight years observed by Verelst et al" and the 1-6% found by Keiderling et al. ' 7 These differences and the lack of a relation between '3'I dose and subsequent development of hypothyroidism in the present study suggests that the individual sensitivity to "'I governs the subsequent development of hypothyroidism. In the present study the risk of hypothyroidism was probably overestimated since all patients receiving levothyroxine were classified as hypothyroid although seven of 11 patients had compensated hypothyroidism. It is well accepted that this condition can be stable for several years before possible progression to manifest hypothyroidism. The risk of hypothyroidism is clearly lower than that reported for Graves' disease and not higher than that reported for nodular toxic goitre.2' Since the main purpose of "'I treatment is to decrease nodular volume the accompanying low incidence of hypothyroidism cannot be classified as a serious side effect. Higher "'I doses might even be contemplated. Since there is evidence of a subtle ongoing reduction in thyroidal secretion in patients remaining clinically euthyroid these patients should be offered prolonged follow up in case ofpossible late hypothyroidism. 22 Side 
